Triple Antithrombotic Therapy: What — and When — Is the Bleeding Risk?
Morten Lamberts, MD, lead investigator of a recent registry study of various combinations of antithrombotic agents in patients with AF and CAD, answers John Ryan's questions about the study and its...
View ArticlePlatelet-Function Testing in Coronary Stenting: Frozen in Its Tracks
An ARCTIC trial investigator discusses possible reasons why antiplatelet-drug and dosing adjustments, guided by platelet-function testing, did not improve clinical outcomes for stented patients.The...
View ArticleSelections from Richard Lehman’s Literature Review: December 3rd
This week's topics include the association between aldosterone-antagonist therapy and mortality and readmission among patients with HF and reduced EF, warfarin therapy after bioprosthetic AVR, and...
View ArticleNo Aspirin After DES? Is This The Wild, Wild WOEST?
According to the recently published results of the WOEST trial, patients receiving anticoagulation thereapy who undergo stenting have better outcomes with clopidogrel only than with clopidogrel plus...
View ArticleSelections from Richard Lehman’s Literature Review: March 11th
This week's topics include antiplatelet therapy to prevent CV events and mortality in those with intermittent claudication, endovascular treatment for stroke, and more.The post Selections from Richard...
View ArticleRivaroxaban Gains Approval in Europe for ACS Indication
Rivaroxaban (Xarelto, Bayer) has been approved in Europe for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction, or stroke) following an acute coronary syndrome...
View ArticleAspirin Therapy with Anticoagulation in Patients with Afib?
An interview with Benjamin Steinberg about an analysis of data from the ORBIT-AF registry, in which patients with atrial fibrillation who were taking oral anticoagulation and aspirin had a higher risk...
View ArticleStudy Supports Loosening Guidelines for Surgery After Stent Implantation
According to current guidelines, noncardiac surgery should be delayed for six weeks after bare-metal stent (BMS) implantation and for one year after drug-eluting stent (DES) implantation, though there...
View ArticleFDA Reviewers Deliver Split Opinion on Cangrelor
FDA reviewers presented two dramatically different views of The Medicines Company’s investigational new drug cangrelor. One reviewer says the drug should not be approved without a new trial and even...
View ArticleSelections from Richard Lehman’s Literature Review: March 23rd
This week's topics include antiplatelet therapy duration following bare metal or drug-eluting coronary stents, thrombolysis in acute ischemic stroke, and more.The post Selections from Richard Lehman’s...
View Article
